文献速递临床试验与 GCP

预防性淋巴重建(LYMbR)预防皮肤恶性肿瘤淋巴结清扫后淋巴水肿:一项随机对照试验

Prophylactic LYMphatic Reconstruction (LYMbR) to prevent lymphedema after node dissection for cutaneous malignancies: a randomized controlled trial.
PubMed 文献 · Trials · 2026-02-26

该Ⅲ期随机对照试验拟纳入因皮肤恶性肿瘤接受腋窝或腹股沟淋巴结清扫的成人患者,按上肢或下肢分层进行区组随机化,比较预防性淋巴管静脉吻合术(LVA)与对照组的淋巴水肿发生率和生活质量,并评估淋巴结清扫相关并发症发生率。研究注册于ClinicalTrials.gov,编号NCT05136079,注册日期2021年11月2日。

要点

  • 该研究为Ⅲ期随机对照试验,评估预防性淋巴管静脉吻合术预防皮肤恶性肿瘤淋巴结清扫后淋巴水肿的疗效与安全性。
  • 主要终点为腋窝或腹股沟淋巴结清扫后淋巴水肿的存在与否及参与者生活质量。
  • 次要终点为淋巴结清扫相关并发症的发生率,按上肢或下肢分层进行区组随机化。

核心结论

  • 研究旨在评估预防性淋巴管静脉吻合术预防皮肤恶性肿瘤淋巴结清扫后淋巴水肿的疗效、安全性和长期结局。
  • 背景指出预防性即刻淋巴重建通过淋巴管静脉吻合术在腋窝和腹股沟淋巴结清扫后可使癌症相关淋巴水肿发生率降低三分之二,但仍需严格的Ⅲ期长期随访研究证实。

研究设计与样本

  • Ⅲ期随机对照试验,纳入因皮肤恶性肿瘤接受腋窝或腹股沟淋巴结清扫的成人患者。
  • 采用区组随机化,按上肢或下肢分层。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 主要终点为腋窝或腹股沟淋巴结清扫后淋巴水肿的存在与否及参与者生活质量。
  • 次要终点为淋巴结清扫相关并发症的发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出仍需严格的Ⅲ期长期随访研究来证实既往有希望的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cancer-related lymphedema (CRLE), a chronic complication of cancer treatment, affects 39-73% of patients post-lymph node dissection, impacting physical health, social participation, and finances. Prophylactic immediate lymphatic reconstruction (ILR) via lymphaticovenous anastomosis (LVA) has shown potential in reducing CRLE incidence by two-thirds following axillary and inguinal node dissection. However, rigorous phase III studies with long-term follow-up are still needed to confirm these promising results. This study aims to evaluate the efficacy, safety, and long-term outcomes of ILR in preventing CRLE in a prospective, controlled trial setting. METHODS/DESIGNS: A phase III randomized controlled trial will evaluate an intervention in adult patients undergoing axillary or groin node dissection for cutaneous malignancy. Block randomization will stratify participants by upper or lower extremities. Primary outcomes include lymphedema incidence and quality-of-life measures. Statistical analyses will compare lymphedema rates and quality-of-life outcomes between intervention and control groups. OBJECTIVES: The primary endpoint is to assess the impact of prophylactic LVA on the presence or absence of lymphedema post axillary or groin lymphadenectomy and participant quality of life. The secondary endpoint is the incidence of complications related to nodal dissection. SIGNIFICANCE: CRLE, a common complication of cancer surgery and radiotherapy, severely impacts patients' lives and healthcare resources. Reducing its incidence by two-thirds would significantly improve outcomes for cancer survivors and decrease treatment demands. This underscores the need for advanced research in prevention and early intervention strategies to mitigate lymphedema's burden on patients and healthcare systems. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT05136079 2021-11-02.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jonsson EL, Wu A, Onysyk T, et al. Prophylactic LYMphatic Reconstruction (LYMbR) to prevent lymphedema after node dissection for cutaneous malignancies: a randomized controlled trial. Trials. 2026. PMID: 41749241. doi:10.1186/s13063-026-09518-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。